CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (23,138)	$ (29,727)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	49	48
Stock-based compensation expense	3,469	5,600
Non-cash interest expense - related party		121
Change in fair value of warrant liability	(7,284)	(473)
Changes in operating assets and liabilities, net of impact of assumed net assets of Macrocure:
Prepaid expenses and other assets	(297)	(99)
Deferred tax assets	20	(158)
Research and development incentive receivable	780	1,458
Accounts payable and accrued expenses	368	1,093
Net cash used in operating activities	(26,033)	(22,137)
Cash flows from investing activities:
Purchases of property and equipment		(64)
Net cash used in investing activities		(64)
Cash flows from financing activities:
Proceeds from issuance of common stock in connection with merger with Macrocure		21,165
Proceeds from issuance of common stock in connection with Subscription Agreement		10,000
Proceeds from issuance of common stock in connection with Private Placement		18,000
Proceeds from issuance of common stock, net of underwriter commissions and discounts	15,034
Proceeds from notes payable - related party		750
Proceeds from exercise of common stock warrants	1,217
Proceeds from the exercise of stock options	14	20
Payment of offering costs	(359)	(2,172)
Net cash provided by financing activities	15,906	47,763
Effect of exchange rate changes on cash and cash equivalents	674	(618)
Net increase (decrease) in cash and cash equivalents	(9,453)	24,944
Cash and cash equivalents at beginning of period	25,737	793
Cash and cash equivalents at end of period	16,284	25,737
Supplemental disclosure of non-cash financing activities:
Accretion of preferred stock to redemption value		244
Reduction in fair value of warrant liability as a result of exercise of common stock warrants	1,130
Deferred offering costs included in accounts payable and accrued expenses	$ 41	131
Conversion of notes payable-related party and accrued interest convertible preferred stock into common stock		31,145
Conversion of convertible preferred stock into common stock		70,775
Value of net assets acquired in connection with merger with Macrocure, excluding cash		$ 96